PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah B. Doroshow(Icahn School of Medicine at Mount Sinai), Fred R. Hirsch(Tisch Hospital), David L. Rimm(Yale University), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center), Sheena Bhalla(Icahn School of Medicine at Mount Sinai), Mary Beth Beasley(Icahn School of Medicine at Mount Sinai), Ming‐Sound Tsao(Kumamoto University), Sacha Gnjatic(Tisch Hospital), Lynette M. Sholl(Brigham and Women's Hospital), Keith M. Kerr(University of Aberdeen)
Cited by 1,549
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k